{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:24:28Z","timestamp":1789169068513,"version":"build-2803163510"},"reference-count":121,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.4065\/mcp.2011.0128","type":"journal-article","created":{"date-parts":[[2011,7,29]],"date-time":"2011-07-29T13:35:25Z","timestamp":1311946525000},"page":"762-780","source":"Crossref","is-referenced-by-count":33,"title":["Opening a New Lipid \u201cApo-thecary\u201d: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk"],"prefix":"10.4065","volume":"86","author":[{"given":"Terry A.","family":"Jacobson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.4065\/mcp.2011.0128_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archinte.1988.00380010040006","article-title":"Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults: the Expert Panel","volume":"148","author":"NCEP Expert Panel","year":"1988","journal-title":"Arch Intern Med"},{"issue":"25","key":"10.4065\/mcp.2011.0128_bib2","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","author":"Adult Treatment Panel","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.4065\/mcp.2011.0128_bib3","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"issue":"8934","key":"10.4065\/mcp.2011.0128_bib4","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"issue":"20","key":"10.4065\/mcp.2011.0128_bib5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"issue":"14","key":"10.4065\/mcp.2011.0128_bib6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"issue":"19","key":"10.4065\/mcp.2011.0128_bib7","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","journal-title":"N Engl J Med"},{"issue":"20","key":"10.4065\/mcp.2011.0128_bib8","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"9326","key":"10.4065\/mcp.2011.0128_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"issue":"9374","key":"10.4065\/mcp.2011.0128_bib10","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"issue":"9435","key":"10.4065\/mcp.2011.0128_bib11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"9364","key":"10.4065\/mcp.2011.0128_bib12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"9493","key":"10.4065\/mcp.2011.0128_bib13","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"9607","key":"10.4065\/mcp.2011.0128_bib14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"issue":"9753","key":"10.4065\/mcp.2011.0128_bib15","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"13","key":"10.4065\/mcp.2011.0128_bib16","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"issue":"14","key":"10.4065\/mcp.2011.0128_bib17","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.4065\/mcp.2011.0128_bib18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.atherosclerosis.2009.07.021","article-title":"Association between dyslipidemia and vascular events in patients treated with statins: report from the UK General Practice Research Database","volume":"208","author":"Sazonov","year":"2010","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.4065\/mcp.2011.0128_bib19","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosissup.2006.05.003","article-title":"Managing diabetic dyslipidaemia\u2014beyond LDL-C:HDL-C and triglycerides","volume":"7","author":"Barter","year":"2006","journal-title":"Atheroscler Suppl"},{"key":"10.4065\/mcp.2011.0128_bib20","series-title":"t's Heart Disease: A Textbook of Cardiovascular Medicine","first-page":"1013","article-title":"Lipoprotein disorders and cardiovascular disease","author":"Genest","year":"2005"},{"issue":"9725","key":"10.4065\/mcp.2011.0128_bib21","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60488-6","article-title":"Lp-PLA(2) and risk of atherosclerotic vascular disease","volume":"375","author":"Rosenson","year":"2010","journal-title":"Lancet"},{"issue":"16","key":"10.4065\/mcp.2011.0128_bib22","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1161\/CIRCULATIONAHA.106.676890","article-title":"Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications","volume":"116","author":"Tabas","year":"2007","journal-title":"Circulation"},{"issue":"3","key":"10.4065\/mcp.2011.0128_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","article-title":"Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel","volume":"259","author":"Barter","year":"2006","journal-title":"J Intern Med"},{"issue":"9634","key":"10.4065\/mcp.2011.0128_bib24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(08)61076-4","article-title":"Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study","volume":"372","author":"McQueen","year":"2008","journal-title":"Lancet"},{"issue":"17","key":"10.4065\/mcp.2011.0128_bib25","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1093\/eurheartj\/ehp221","article-title":"The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls","volume":"30","author":"Parish","year":"2009","journal-title":"Eur Heart J"},{"issue":"9","key":"10.4065\/mcp.2011.0128_bib26","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-146-9-200705010-00007","article-title":"Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk","volume":"146","author":"van der Steeg","year":"2007","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.4065\/mcp.2011.0128_bib27","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.2337\/diacare.27.8.1991","article-title":"Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes","volume":"27","author":"Jiang","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.4065\/mcp.2011.0128_bib28","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00125-006-0195-6","article-title":"Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study","volume":"49","author":"Bruno","year":"2006","journal-title":"Diabetologia"},{"issue":"2","key":"10.4065\/mcp.2011.0128_bib29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.atherosclerosis.2004.07.019","article-title":"Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome","volume":"177","author":"Corsetti","year":"2004","journal-title":"Atherosclerosis"},{"issue":"9298","key":"10.4065\/mcp.2011.0128_bib30","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","article-title":"High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study","volume":"358","author":"Walldius","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"10.4065\/mcp.2011.0128_bib31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2796.2006.01649.x","article-title":"Errors that result from using the TC\/HDL C ratio rather than the apoB\/apoA-I ratio to identify the lipoprotein-related risk of vascular disease","volume":"259","author":"Sniderman","year":"2006","journal-title":"J Intern Med"},{"issue":"10","key":"10.4065\/mcp.2011.0128_bib32","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"issue":"8","key":"10.4065\/mcp.2011.0128_bib33","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.amjcard.2006.05.024","article-title":"A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease","volume":"98","author":"Hsia","year":"2006","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.4065\/mcp.2011.0128_bib34","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/eurheartj\/ehn347","article-title":"Concentration of apolipoprotein B is comparable with the apolipoprotein B\/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population","volume":"30","author":"Sierra-Johnson","year":"2009","journal-title":"Eur Heart J"},{"issue":"3","key":"10.4065\/mcp.2011.0128_bib35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1161\/01.ATV.0000255580.73689.8e","article-title":"Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study","volume":"27","author":"Benn","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.4065\/mcp.2011.0128_bib36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.atherosclerosis.2005.02.009","article-title":"Inflammatory markers and long-term risk of ischemic heart disease in men: a 13-year follow-up of the Quebec Cardiovascular Study","volume":"182","author":"St-Pierre","year":"2005","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.4065\/mcp.2011.0128_bib37","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/01.ATV.0000154144.73236.f4","article-title":"Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study","volume":"25","author":"St-Pierre","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.4065\/mcp.2011.0128_bib38","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.amjcard.2005.10.060","article-title":"Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men","volume":"97","author":"St-Pierre","year":"2006","journal-title":"Am J Cardiol"},{"issue":"22","key":"10.4065\/mcp.2011.0128_bib39","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1161\/CIRCULATIONAHA.104.532499","article-title":"Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men","volume":"112","author":"Pischon","year":"2005","journal-title":"Circulation"},{"issue":"18","key":"10.4065\/mcp.2011.0128_bib40","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1161\/01.CIR.0000146339.57154.9B","article-title":"Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines","volume":"110","author":"Shai","year":"2004","journal-title":"Circulation"},{"issue":"11","key":"10.4065\/mcp.2011.0128_bib41","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.jacc.2006.09.030","article-title":"The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women","volume":"48","author":"Everett","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"10.4065\/mcp.2011.0128_bib42","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Emerging Risk Factors Collaboration","year":"2009","journal-title":"JAMA"},{"issue":"15","key":"10.4065\/mcp.2011.0128_bib43","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.97.15.1453","article-title":"Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)","volume":"97","author":"Pedersen","year":"1998","journal-title":"Circulation"},{"issue":"10","key":"10.4065\/mcp.2011.0128_bib44","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/hc1002.105136","article-title":"Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?","volume":"105","author":"Simes","year":"2002","journal-title":"Circulation"},{"issue":"5","key":"10.4065\/mcp.2011.0128_bib45","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/01.CIR.101.5.477","article-title":"Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS)","volume":"101","author":"Gotto","year":"2000","journal-title":"Circulation"},{"issue":"19","key":"10.4065\/mcp.2011.0128_bib46","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"issue":"6","key":"10.4065\/mcp.2011.0128_bib47","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/07853890801964955","article-title":"Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease: insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL)","volume":"40","author":"Holme","year":"2008","journal-title":"Ann Med"},{"issue":"3","key":"10.4065\/mcp.2011.0128_bib48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1373\/clinchem.2008.111401","article-title":"Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"55","author":"Charlton-Menys","year":"2009","journal-title":"Clin Chem"},{"issue":"2","key":"10.4065\/mcp.2011.0128_bib49","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00125-008-1176-8","article-title":"Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"52","author":"Charlton-Menys","year":"2009","journal-title":"Diabetologia"},{"issue":"23","key":"10.4065\/mcp.2011.0128_bib50","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"issue":"5","key":"10.4065\/mcp.2011.0128_bib51","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4065\/mcp.2009.0517","article-title":"Using apolipoprotein B to manage dyslipidemic patients: time for a change?","volume":"85","author":"Harper","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.4065\/mcp.2011.0128_bib52","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/01.ATV.13.2.170","article-title":"Effects of simvastatin on apoB metabolism and LDL subfraction distribution","volume":"13","author":"Gaw","year":"1993","journal-title":"Arterioscler Thromb"},{"issue":"2","key":"10.4065\/mcp.2011.0128_bib53","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.atherosclerosis.2003.08.025","article-title":"Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia","volume":"171","author":"Caslake","year":"2003","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.4065\/mcp.2011.0128_bib54","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jacc.2008.04.052","volume":"52","author":"Ballantyne","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.4065\/mcp.2011.0128_bib55","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2337\/dc08-9018","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation","volume":"31","author":"Brunzell","year":"2008","journal-title":"Diabetes Care"},{"issue":"3","key":"10.4065\/mcp.2011.0128_bib56","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/157016109788340703","article-title":"Future challenges for microsomal transport protein inhibitors","volume":"7","author":"Wierzbicki","year":"2009","journal-title":"Curr Vasc Pharmacol"},{"issue":"15","key":"10.4065\/mcp.2011.0128_bib57","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2009.11.069","article-title":"Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy","volume":"55","author":"Akdim","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.4065\/mcp.2011.0128_bib58","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"10.4065\/mcp.2011.0128_bib59","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.clinthera.2004.09.006","article-title":"Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial","volume":"26","author":"Jones","year":"2004","journal-title":"Clin Ther"},{"issue":"1","key":"10.4065\/mcp.2011.0128_bib60","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/01.CIR.88.1.20","article-title":"Beneficial effects of colestipol-niacin therapy on the common carotid artery: two- and four-year reduction of intima-media thickness measured by ultrasound","volume":"88","author":"Blankenhorn","year":"1993","journal-title":"Circulation"},{"issue":"19","key":"10.4065\/mcp.2011.0128_bib61","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"issue":"22","key":"10.4065\/mcp.2011.0128_bib62","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease?","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"issue":"9500","key":"10.4065\/mcp.2011.0128_bib63","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"6","key":"10.4065\/mcp.2011.0128_bib64","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"issue":"12","key":"10.4065\/mcp.2011.0128_bib65","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"issue":"4","key":"10.4065\/mcp.2011.0128_bib66","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"Coronary Drug Project Research Group","year":"1975","journal-title":"JAMA"},{"issue":"10","key":"10.4065\/mcp.2011.0128_bib67","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.amjcard.2008.02.092","article-title":"Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)","volume":"101","author":"Ballantyne","year":"2008","journal-title":"Am J Cardiol"},{"issue":"16","key":"10.4065\/mcp.2011.0128_bib68","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2008.03.003","article-title":"Lipid-altering efficacy and safety of ezetimibe\/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia","volume":"51","author":"Guyton","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.4065\/mcp.2011.0128_bib69","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.atherosclerosis.2006.11.037","article-title":"Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin 66 or ezetimibe versus a statin alone (the COMPELL study)","volume":"192","author":"McKenney","year":"2007","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.4065\/mcp.2011.0128_bib70","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2337\/diacare.26.5.1513","article-title":"Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT)","volume":"26","author":"Robins","year":"2003","journal-title":"Diabetes Care"},{"issue":"17","key":"10.4065\/mcp.2011.0128_bib71","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.4065\/mcp.2011.0128_bib72","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1007\/s00125-010-1806-9","article-title":"Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes","volume":"53","author":"Taskinen","year":"2010","journal-title":"Diabetologia"},{"issue":"1","key":"10.4065\/mcp.2011.0128_bib73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/clp.10.84","article-title":"The ACCORD-Lipid study: implications for treatment of dyslipidemia in type 2 diabetes mellitus","volume":"6","author":"Elam","year":"2011","journal-title":"Clin Lipidol"},{"issue":"2","key":"10.4065\/mcp.2011.0128_bib74","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and metaanalysis","volume":"57","author":"Bruckert","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"10.4065\/mcp.2011.0128_bib75","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/11533430-000000000-00000","article-title":"Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study","volume":"10","author":"Roth","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"10.4065\/mcp.2011.0128_bib76","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.amjcard.2008.10.025","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia","volume":"103","author":"Goldberg","year":"2009","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.4065\/mcp.2011.0128_bib77","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.atherosclerosis.2008.09.027","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study","volume":"204","author":"Jones","year":"2009","journal-title":"Atherosclerosis"},{"issue":"5\u20136","key":"10.4065\/mcp.2011.0128_bib78","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10557-010-6266-4","article-title":"Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia: a phase 3 study","volume":"24","author":"Roth","year":"2010","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.4065\/mcp.2011.0128_bib79","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ahj.2008.08.027","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study","volume":"157","author":"Mohiuddin","year":"2009","journal-title":"Am Heart J"},{"issue":"4","key":"10.4065\/mcp.2011.0128_bib80","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.amjcard.2009.04.018","article-title":"Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial)","volume":"104","author":"Grundy","year":"2009","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.4065\/mcp.2011.0128_bib81","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1016\/j.clinthera.2009.12.007","article-title":"Efficacy and tolerability of atorvastatin\/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study","volume":"31","author":"Davidson","year":"2009","journal-title":"Clin Ther"},{"issue":"4","key":"10.4065\/mcp.2011.0128_bib82","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)","volume":"95","author":"Grundy","year":"2005","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.4065\/mcp.2011.0128_bib83","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","article-title":"Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease","volume":"160","author":"SHARP Collaborative Group","year":"2010","journal-title":"Am Heart J"},{"issue":"13","key":"10.4065\/mcp.2011.0128_bib84","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rosseb\u00f8","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"10.4065\/mcp.2011.0128_bib85","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.amjcard.2010.01.363","article-title":"Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial","volume":"105","author":"Holme","year":"2010","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.4065\/mcp.2011.0128_bib86","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","article-title":"Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)","volume":"99","author":"Ballantyne","year":"2007","journal-title":"Am J Cardiol"},{"issue":"23","key":"10.4065\/mcp.2011.0128_bib87","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA"},{"issue":"23","key":"10.4065\/mcp.2011.0128_bib88","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"issue":"9567","key":"10.4065\/mcp.2011.0128_bib89","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"issue":"9177","key":"10.4065\/mcp.2011.0128_bib90","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial [published corrections appear in Lancet. 2007;369(9556):106 and 2001;357(9256):642]","volume":"354","author":"GISSI Study Group (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico)","year":"1999","journal-title":"Lancet"},{"issue":"2","key":"10.4065\/mcp.2011.0128_bib91","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11883-007-0011-x","article-title":"Beyond lipids: the role of omega-3 fatty acids from fish oil in the prevention of coronary heart disease","volume":"9","author":"Jacobson","year":"2007","journal-title":"Curr Atheroscler Rep"},{"issue":"5","key":"10.4065\/mcp.2011.0128_bib92","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clinthera.2007.05.002","article-title":"Hypertriglyceridemia and cardiovascular risk reduction","volume":"29","author":"Jacobson","year":"2007","journal-title":"Clin Ther"},{"issue":"4","key":"10.4065\/mcp.2011.0128_bib93","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.amjcard.2008.03.078","article-title":"Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg\/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia","volume":"102","author":"Maki","year":"2008","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.4065\/mcp.2011.0128_bib94","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4065\/mcp.2009.0397","article-title":"Effects of prescription omega-3-acid ethyl esters on non\u2013high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin","volume":"85","author":"Bays","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"21","key":"10.4065\/mcp.2011.0128_bib95","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","article-title":"n-3 fatty acids and cardiovascular events after myocardial infarction","volume":"363","author":"Kromhout","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.4065\/mcp.2011.0128_bib96","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0828-282X(09)70715-9","article-title":"2009 Canadian Cardiovascular Society\/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult\u20142009 recommendations","volume":"25","author":"Genest","year":"2009","journal-title":"Can J Cardiol"},{"key":"10.4065\/mcp.2011.0128_bib97","author":"NHANES Investigators"},{"issue":"11","key":"10.4065\/mcp.2011.0128_bib98","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2004.03.046","article-title":"Optimal low-density lipoprotein is 50 to 70 mg\/dl: lower is better and physiologically normal","volume":"43","author":"O'Keefe","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.4065\/mcp.2011.0128_bib99","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11883-009-0054-2","article-title":"ApoB versus non-HDL-C: what to do when they disagree","volume":"11","author":"Sniderman","year":"2009","journal-title":"Curr Atheroscler Rep"},{"issue":"15","key":"10.4065\/mcp.2011.0128_bib100","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jacc.2008.02.034","article-title":"Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation","volume":"51","author":"Brunzell","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.4065\/mcp.2011.0128_bib101","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jacl.2007.12.006","article-title":"Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice","volume":"2","author":"Sniderman","year":"2008","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.4065\/mcp.2011.0128_bib102","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacl.2010.01.005","article-title":"When is equal not equal?","volume":"4","author":"Sniderman","year":"2010","journal-title":"J Clin Lipidol"},{"issue":"21","key":"10.4065\/mcp.2011.0128_bib103","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein?","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"9359","key":"10.4065\/mcp.2011.0128_bib104","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)12663-3","article-title":"Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment","volume":"361","author":"Sniderman","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.4065\/mcp.2011.0128_bib105","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2796.2006.01643.x","article-title":"The apoB\/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy\u2014a review of the evidence","volume":"259","author":"Walldius","year":"2006","journal-title":"J Intern Med"},{"issue":"2","key":"10.4065\/mcp.2011.0128_bib106","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1185\/030079907X253906","article-title":"ApoB\/A1 and LDL-C\/HDL-C and the prediction of cardiovascular risk in statin-treated patients","volume":"24","author":"Liem","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"10.4065\/mcp.2011.0128_bib107","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1515\/CCLM.2004.254","article-title":"The apoB\/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk","volume":"42","author":"Walldius","year":"2004","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"10.4065\/mcp.2011.0128_bib108","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4065\/mcp.2010.0058","article-title":"To B or not to B: is non-high-density lipoprotein cholesterol an adequate surrogate for apolipoprotein B?","volume":"85","author":"Lavie","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/mcp.2011.0128_bib109","unstructured":"Ramjee V, Sperling LS, Jacobson TA. Non-HDL versus ApoB in cardiovascular risk stratification: do the math. J Am Coll Cardiol. In press."},{"issue":"3","key":"10.4065\/mcp.2011.0128_bib110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","article-title":"A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk","volume":"4","author":"Sniderman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"7","key":"10.4065\/mcp.2011.0128_bib111","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1161\/01.ATV.0000022850.59845.E0","article-title":"Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I\/A-II in prediction of coronary heart disease: the PRIME Study","volume":"22","author":"Luc","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.4065\/mcp.2011.0128_bib112","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/eurheartj\/ehi003","article-title":"Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA\/KORA Augsburg cohort study","volume":"26","author":"Meisinger","year":"2005","journal-title":"Eur Heart J"},{"key":"10.4065\/mcp.2011.0128_bib113","doi-asserted-by":"crossref","first-page":"b92","DOI":"10.1136\/bmj.b92","article-title":"Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis","volume":"338","author":"Briel","year":"2009","journal-title":"BMJ"},{"issue":"4","key":"10.4065\/mcp.2011.0128_bib114","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.amjcard.2005.04.019","article-title":"Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations","volume":"96","author":"Davidson","year":"2005","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.4065\/mcp.2011.0128_bib115","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2009.12.023","article-title":"Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis","volume":"210","author":"Bruckert","year":"2010","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.4065\/mcp.2011.0128_bib116","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/met.2009.0007","article-title":"Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis","volume":"7","author":"Jialal","year":"2009","journal-title":"Metab Syndr Relat Disord"},{"issue":"9729","key":"10.4065\/mcp.2011.0128_bib117","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.4065\/mcp.2011.0128_bib118","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrendo.2009.151","article-title":"Myopathy with statin-fibrate combination therapy: clinical considerations","volume":"5","author":"Jacobson","year":"2009","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10.4065\/mcp.2011.0128_bib119","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0025-6196(11)60897-5","article-title":"Toward \u201cpain-free\u201d statin prescribing: clinical algorithm for diagnosis and management of myalgia","volume":"83","author":"Jacobson","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"17","key":"10.4065\/mcp.2011.0128_bib120","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.109.192278","article-title":"Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association","volume":"119","author":"Hlatky","year":"2009","journal-title":"Circulation"},{"issue":"8","key":"10.4065\/mcp.2011.0128_bib121","doi-asserted-by":"crossref","first-page":"769","DOI":"10.4065\/mcp.2010.0378","article-title":"Using apolipoprotein B to manage dyslipidemia [letter reply]","volume":"85","author":"Jacobson","year":"2010","journal-title":"Mayo Clin Proc"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611651781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611651781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T11:22:35Z","timestamp":1560424955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611651781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":121,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0025619611651781"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2011.0128","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}